Showing 7731-7740 of 20882 results for "".
- Do You Really Need to Walk 10,000 Steps to See Health Benefits?https://reachmd.com/news/do-you-really-need-to-walk-10000-steps-to-see-health-benefits/2457137/A new meta-study of 12 other studies brings clarity to confusion regarding the most beneficial number of steps one should walk each day.The study indicates that benefits begin with as few as around 2,500 da
- Effort to Cure Corneal Blindness Globally Welcomes $35 Million Supporthttps://reachmd.com/news/effort-to-cure-corneal-blindness-globally-welcomes-35-million-support/2457101/University of Melbourne Professor Greg Qiao, a BIENCO Chief Investigator, inspects a transparent hydrogel scaffold. Photo credit: Cesar Nicolas
- Study Reveals Mechanism That Aggravates Tuberculosis and Reduces Survival Rateshttps://reachmd.com/news/study-reveals-mechanism-that-aggravates-tuberculosis-and-reduces-survival-rates/2457121/Tuberculosis (TB) is a highly infectious disease caused by the bacterium Mycobacterium tuberculosis. It primarily affects the lungs but can also affect other parts of the body. According to the World Health Organization (WHO), TB is one of the top 10
- Blood Test Predicts Psychosis Risk, Most Effective Treatmentshttps://reachmd.com/news/blood-test-predicts-psychosis-risk-most-effective-treatments/2457133/INDIANAPOLIS — A team of researchers led by Indiana University School of Medicine faculty have developed a breakthrough new blood test for schizophrenia, a psychiatric disorder that includes hallucinations and delusions. Schizophrenia and related psychotic disorders affect o
- UL Research Confirms Benefits of Resistance Exercise Training in Treatment of Anxiety and Depressionhttps://reachmd.com/news/ul-research-confirms-benefits-of-resistance-exercise-training-in-treatment-of-anxiety-and-depression/2457131/A new study by researchers at University of Limerick has demonstrated the impact resistance exercise training can have in the treatment of anxiety and depressive symptoms. The new study provides evidence to
- Ketamine’s Promise for Severe Depression Grows, But Major Questions Remainhttps://reachmd.com/news/ketamines-promise-for-severe-depression-grows-but-major-questions-remain/2457132/Using an old anesthesia drug to pull people out of the depths of severe depression has gone from fringe idea to widespread use in just a few years.Sparked by promising studies and stories of lives transformed, clinics offering intravenous infusions of ketamine have popped up nati
- Chapman Scientists Use ChatGPT to Develop New Medicinehttps://reachmd.com/news/chapman-scientists-use-chatgpt-to-develop-new-medicine/2457102/Generative artificial intelligence platforms, from ChatGPT to Midjourney, grabbed headlines in 2023. But GenAI can do more than create collaged images and help write emails — it can also design new drugs to treat disease.Today, scientists use advanced technology to design ne
- Eli Lilly Says Weight Loss Drug Shows Promise as Treatment for Fatty Liver Diseasehttps://reachmd.com/news/eli-lilly-says-weight-loss-drug-shows-promise-as-treatment-for-fatty-liver-disease/2457117/An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. Brendan McDermid | ReutersEli Lilly
- Biogen Announces Cancelation of Aduhelm, Redirection Towards Leqembihttps://reachmd.com/news/biogen-announces-cancelation-of-aduhelm-redirection-towards-leqembi/2457109/Biogen (Cambridge, MA) has canceled the development and commercialization of Aduhelm (aducanumab; Biogen, Cambridge, MA), and is strategically redirecting resources towards other assets in its Alzheimer disease (AD) pipeline, particularly Leqembi (lecanumab-irmb; Eisai, Tokyo, Japan
- Unveiling Potential Diagnostic, Treatment Target for APS-Related Thrombocytopeniahttps://reachmd.com/news/unveiling-potential-diagnostic-treatment-target-for-aps-related-thrombocytopenia/2457134/BYLINE: Valerie Goodwin Newswise — Blood clots and pregnancy loss are commonly recognized features of antiphospholipid syndrome, but thrombocytopenia is the third most prevalent symptom, impacting up to half of antiphospholipid syndrome patients.